Research
Hormonal
Untreated diabetic patients fail to increase adipose tissue lipoprotein lipase (LPL) activity in response to high-carbohydrate feeding due to defective insulin secretion, whereas control subjects show marked increases.
In untreated diabetes, the body's normal response to eating carbohydrates (increasing fat-storage enzymes) is broken because insulin secretion is low. This contributes to hypertriglyceridemia.
GoodRefutesHIGH confidence
In contrast, the diabetic patients with low insulin responses, failed activity with feeding. ... In contrast to the results in control subjects, heparin-releasable LPL and acetone-ether powder LPL did not increase significantly on the fat-free high carbohydrate diet in diabetic subjects
Why this rating
Clear contrast between groups with statistical significance.
Source
Determinants of human adipose tissue lipoprotein lipase. Effect of diabetes and obesity on basal- and diet-induced activity.
Olavi Pykälistö et al. · Journal of Clinical Investigation · 1975
DOI 10.1172/jci108185
mechanism_only · n=23Cited 286×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Insulin is the primary regulator of human adipose tissue lipoprotein lipase (LPL) activity; insulin deficiency (as in untreated diabetes) significantly reduces LPL activity, while elevated insulin levels (as in obesity or post-prandial states) increase it.Good
- Dietary carbohydrate intake drives post-prandial increases in adipose tissue lipoprotein lipase (LPL) activity via insulin secretion; high-carbohydrate, fat-free diets significantly increase LPL, whereas fat-containing diets do not.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →